<DOC>
	<DOC>NCT00810758</DOC>
	<brief_summary>To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of PF-04878691.</brief_summary>
	<brief_title>Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 1855, inclusive. Body Mass Index (BMI) of 1830 kg/m2; total body weight &gt;50kg (110lbs). Pregnant or nursing females. Females of childbearing potential. Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, allergic or autoimmune disease or clinical findings at screening. Smoking within the previous 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>HCV</keyword>
	<keyword>Toll-like receptor 7</keyword>
	<keyword>Multiple oral dose escalation study of PF-04878691</keyword>
</DOC>